Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / COM
-
Number of holders
-
32
-
Total 13F shares, excl. options
-
2,656,706
-
Shares change
-
+831,235
-
Total reported value, excl. options
-
$5,066,902
-
Value change
-
+$1,576,755
-
Put/Call ratio
-
1.04%
-
Number of buys
-
22
-
Number of sells
-
-3
-
Price
-
$1.91
Significant Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q1 2025
36 filings reported holding GANX - Gain Therapeutics, Inc. - COM as of Q1 2025.
Gain Therapeutics, Inc. - COM (GANX) has 32 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2,656,706 shares
.
Largest 10 shareholders include DME Capital Management, LP (566,130 shares), JONES FINANCIAL COMPANIES LLLP (427,700 shares), GEODE CAPITAL MANAGEMENT, LLC (282,211 shares), VANGUARD GROUP INC (254,990 shares), MARSHALL WACE, LLP (196,026 shares), Dauntless Investment Group, LLC (125,584 shares), NORTHERN TRUST CORP (100,170 shares), MORGAN STANLEY (99,795 shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (85,958 shares), and BlackRock, Inc. (84,407 shares).
This table shows the top 32 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.